We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-4.28%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.25B
AUM Growth
+$280M
Cap. Flow
+$431M
Cap. Flow %
13.28%
Top 10 Hldgs %
47.18%
Holding
44
New
10
Increased
12
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$110M
2
UHS icon
Universal Health Services
UHS
+$102M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$90.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$38.5M
5
SNY icon
Sanofi
SNY
+$38.1M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$71.4M
2
SKIN icon
SkinHealth Systems
SKIN
+$67.2M
3
ALKS icon
Alkermes
ALKS
+$44.5M
4
HOLX
Hologic
HOLX
+$44.4M
5
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 79.7%
2 Technology 2.58%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
1
Universal Health Services
UHS
$10.2B
$201M 6.18%
1,450,000
+675,000
+87% +$102M
WBA
2
DELISTED
Walgreens Boots Alliance
WBA
$188M 5.8%
4,000,000
+500,000
+14% +$24.1M
THC icon
3
Tenet Healthcare
THC
$22.2B
$183M 5.63%
2,750,000
-100,000
-4% -$7.09M
NVS icon
4
CALL
Novartis
NVS
$302B
$164M 5.04%
+2,000,000
New +$180M
VTRS icon
5
Viatris
VTRS
$20.8B
$163M 5.01%
12,000,000
– –
MRK icon
6
CALL
Merck
MRK
$322B
$150M 4.63%
2,000,000
– –
SNY icon
7
Sanofi
SNY
$107B
$145M 4.45%
3,000,000
+750,000
+33% +$38.1M
PRGO icon
8
Perrigo
PRGO
$1.44B
$118M 3.64%
2,500,000
– –
MRK icon
9
Merck
MRK
$322B
$113M 3.47%
1,500,000
– –
HCA icon
10
HCA Healthcare
HCA
$88.4B
$109M 3.34%
447,500
-152,500
-25% -$37.3M
ZBH icon
11
Zimmer Biomet
ZBH
$18.8B
$106M 3.27%
+746,843
New +$110M
GSK icon
12
GSK
GSK
$107B
$105M 3.24%
2,200,000
– –
GILD icon
13
CALL
Gilead Sciences
GILD
$165B
$105M 3.23%
1,500,000
+500,000
+50% +$35.1M
BKD icon
14
Brookdale Senior Living
BKD
$3.55B
$101M 3.1%
16,000,000
+650,000
+4% +$4.64M
AZN icon
15
CALL
AstraZeneca
AZN
$269B
$90.1M 2.77%
750,000
-250,000
-25% -$29.1M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.9B
$88.9M 2.74%
+1,150,000
New +$90.7M
MYGN icon
17
Myriad Genetics
MYGN
$476M
$88.8M 2.73%
2,750,000
-250,000
-8% -$8.3M
ALKS icon
18
Alkermes
ALKS
$8.11B
$84M 2.59%
2,725,000
-1,575,000
-37% -$44.5M
IONS icon
19
Ionis Pharmaceuticals
IONS
$8.93B
$83.8M 2.58%
2,500,000
+500,000
+25% +$18.8M
CHNG
20
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$83.8M 2.58%
4,000,000
+1,650,000
+70% +$36M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$79.6M 2.45%
450,000
+50,000
+13% +$8.04M
GILD icon
22
Gilead Sciences
GILD
$165B
$76.8M 2.37%
1,100,000
-300,000
-21% -$21.1M
IRWD icon
23
Ironwood Pharmaceuticals
IRWD
$586M
$71.8M 2.21%
5,500,000
-2,000,000
-27% -$25.8M
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$68.9M 2.12%
685,000
+220,000
+47% +$25.8M
NKTR icon
25
Nektar Therapeutics
NKTR
$2.39B
$67.3M 2.07%
250,000
+16,667
+7% +$4.01M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Camber Capital Management held 44 positions worth $3.25B, up 9.4% from $2.97B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Camber Capital Management deployed $431M of net new capital in Q3 2021, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Zimmer Biomet: 746,843 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Alkermes, an estimated $44.5M trimmed.

  • Camber Capital Management's largest Q3 2021 buy was Zimmer Biomet: 746,843 shares worth $106M.
  • Camber Capital Management added most to Universal Health Services in Q3 2021, an estimated $102M increase.
  • Camber Capital Management's biggest Q3 2021 reduction was Alkermes, cutting an estimated $44.5M.
  • Camber Capital Management fully exited Cardinal Health in Q3 2021, selling an estimated $71.4M.
  • Camber Capital Management's ten largest holdings make up 47% of its $3.25B portfolio in Q3 2021.
  • Camber Capital Management opened 10 new positions and closed 5 in Q3 2021.
  • Camber Capital Management's portfolio value rose 9.4% quarter-over-quarter to $3.25B.

Based on Camber Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.